Publications by authors named "Max Tsai"

Claim this Profile
I
Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
Debra Luffer-Atlas, Darren Wilbraham, Maria M Posada, John Landry, Max Tsai

J Clin Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults.
Wei Yin, Axel Facius, Thomas Wagner, Max Tsai, Mahnaz Asgharnejad

Clin Transl Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson Disease.
Darren Wilbraham, Kevin M Biglan, Kjell A Svensson, Max Tsai, Melissa Pugh

Clin Pharmacol Drug Dev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine.
Max Tsai, Emel Serap Monkul Nery, Lisa Kerr, Rashna Khanna, Mika Komori

Clin Pharmacokinet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
James Gilleen, Yakub Farah, Cate Davison, Sarah Kerins, Lorena Valdearenas, Max Tsai

Psychopharmacology (Berl)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator (D1PAM), in Healthy Subjects.
Darren Wilbraham, Kevin M Biglan, Kjell A Svensson, Max Tsai, William Kielbasa

Clin Pharmacol Drug Dev· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
James Gilleen, Judith Nottage, Farah Yakub, Sarah Kerins, Lorena Valdearenas, Max Tsai

J Psychopharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.
Eric M Pearlman, Darren Wilbraham, Ellen B Dennehy, Paul H Berg, Max Tsai

Hum Psychopharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol.
Max Tsai, Michael Case, Paul Ardayfio, Helen Hochstetler, Darren Wilbraham

Clin Pharmacol Drug Dev· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study.
Darren Wilbraham, Paul H Berg, Max Tsai, Emily Liffick, Li Shen Loo

J Clin Pharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
Arjan Blokland, Marlies A Van Duinen, Anke Sambeth, Pim R A Heckman, Max Tsai

Neurobiol Aging· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[C]Rolipram.
Akihiro Takano, Tolga Uz, Jesus Garcia-Segovia, Max Tsai, Gezim Lahu

Mol Imaging Biol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.
Paul Goldsmith, John Affinito, Maggie McCue, Max Tsai, Stefan Roepcke

Drugs R D· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis.
Himanshu Naik, Max C Tsai, Jill Fiedler-Kelly, Ping Qiu, Majid Vakilynejad

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Caroline Dudkowski, Max Tsai, Jie Liu, Zhen Zhao, Eric Schmidt

Eur J Clin Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor.
Akihiro Takano, Per Stenkrona, Vladimir Stepanov, Nahid Amini, Stefan Martinsson, Max Tsai

Neuroimage· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.
Max Tsai, Lambros Chrones, Jinhui Xie, Hakop Gevorkyan, Thomas A Macek

Psychopharmacology (Berl)· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension.
Max C Tsai, Jingtao Wu, Stuart Kupfer, Majid Vakilynejad

J Clin Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults.
Nicholas J A Webb, Thomas Wells, Max Tsai, Zhen Zhao, Attila Juhasz

Eur J Clin Pharmacol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors.
Ze Lu, Max Tsai, Jie Wang, David J Cole, M Guillaume Wientjes

Curr Cancer Drug Targets· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiscale tumor spatiokinetic model for intraperitoneal therapy.
Jessie L-S Au, Peng Guo, Yue Gao, Ze Lu, Michael G Wientjes, Max Tsai

AAPS J· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics.
Max Tsai, Ze Lu, M Guillaume Wientjes, Jessie L-S Au

J Control Release· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.
Max Tsai, Jing-tao Wu, Lhanoo Gunawardhana, Himanshu Naik

Int J Clin Pharmacol Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.
Ze Lu, Max Tsai, Dan Lu, Jie Wang, M Guillaume Wientjes

J Pharmacol Exp Ther· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel.
Max Tsai, Ze Lu, Jie Wang, Teng-Kuang Yeh, M Guillaume Wientjes

Pharm Res· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis